A phase Ib/II study of cabozantinib (XL184) with or without erlotinib in patients with non-small cell lung cancer
doi: 10.1016/j.xcrm.2025.101928 50 RashmiRJayachandranKZhangJMenonVMuhammadNZahnerMet al
A framework for evaluating peptides: mechanism, evidence, safety, and regulatory context [10:00]
Presenters will include faculty, graduate, and undergraduate students from Kentucky institutions and organizations directly involved in projects that support NASA missions and Kentuckys science and technology initiatives, with added focus for this session on R&D at the University of Louisville
Influence of dietary deprivation on plasma concentration of free amino acids of man
Much of the reported 40% lean mass loss with GLP-1 use is coming from the liver, explained exercise physiologist Keith Baar, a professor of Neurobiology, Physiology and Behavior and Physiology and Membrane Biology